“BEECH”, a phase I/II study of the AKT inhibitor AZD5363 combined with paclitaxel in patients with advanced or metastatic breast cancer: results from the dose-finding study, including quantitative assessment of circulating tumor DNA as a s
Authors
Turner, NOliveira, M
Armstrong, Anne C
Sablin, M
Perez-Fidalgo, J
Herebien, S
Garcia-Murillas, I
Johnson, S
Foxley, A
Mahmood, A
Lindemann, J
Affiliation
The Royal Marsden Hospital, LondonIssue Date
2015-08-02
Metadata
Show full item recordCitation
“BEECH”, a phase I/II study of the AKT inhibitor AZD5363 combined with paclitaxel in patients with advanced or metastatic breast cancer: results from the dose-finding study, including quantitative assessment of circulating tumor DNA as a s 2015, 75 (15 Supplement):CT331 Cancer ResJournal
Cancer ResearchDOI
10.1158/1538-7445.AM2015-CT331Type
Meetings and ProceedingsLanguage
enISSN
0008-54721538-7445
ae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.AM2015-CT331